A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
News|Articles|February 1, 2002
Study cautions against overtreatment when adopting new NCEP III guidelines
Clinicians must use caution in adopting newly revised national guidelines for treating elevated cholesterol, concludes a new study from the University of Maryland Pharmaceutical Health Services Research Department.
Advertisement
Advertisement
Related to this article
Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using VR.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Systemic inflammation present even in mild hidradenitis suppurativa
2
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
3
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
4
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
5